Autoimmune Diseases  >>  NovoLog (insulin aspart)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NovoLog (insulin aspart) / Novo Nordisk
NCT00539396: A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Completed
2
110
US
Technosphere Insulin
Mannkind Corporation
Diabetes Mellitus, Type 1
 
12/05
NCT00612040 / 2007-002474-60: Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

Completed
2
178
US, Europe, RoW
insulin degludec, insulin glargine, insulin aspart
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
06/08
06/08
NCT00841087: Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes

Completed
2
65
Japan
insulin degludec, insulin detemir, insulin aspart
Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
05/09
05/09
NCT00797823: Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Completed
2
14
US
Insulin, Asp(B28)-, Aspart insulin, Novolog, Glucagon, Glucagen, Placebo, Normal saline, NaCl 0.9%
Legacy Health System, Juvenile Diabetes Research Foundation, Oregon Health and Science University
Type 1 Diabetes
09/09
09/09
NCT01755416: Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

Completed
2
18
US
Closed loop with sensor and Insulin, Novolog, Closed loop with sensor, Insulin and Liraglutide, Victoza
Albert Einstein College of Medicine, Medtronic
Type 1 Diabetes
01/15
01/15

Download Options